So far in H2, Demant has witnessed positive momentum/recovery across most hearing-related sub-segments. Particularly, Oticon More was able to gain market share in the VA channel and posted strong growth in the NHS as well. Although EPOS remained under pressure. 2021 adjusted EBIT guidance was increased marginally while top-line growth guidance was maintained. As our estimates are already on the higher side, we don’t expect any major changes and our cautious recommendation should be maintained.